Testosterone replacement therapy in male urolithiasis patients with metabolic syndrome

Cover Page

Cite item

Full Text

Abstract

Urolithiasis is one of the most wide-spread kidney lesions in males and females all over the world. It is particularly important for males with hypogonadism and metabolic syndrome.

The goal of the study is to assess the effectiveness and safety of Testosterone replacement therapy in males with hypogonadism and metabolic syndrome. Patients and methods. 465 male urolithiasis patients were studied. Mean age was 46 (38-54 years). All patients involved in the study had excessive body mass and obesity of various extent. Mean body mass was 92 (85-97 kg) and body mass index 40.5. More than 50% of the patients had Ischaemic Heart Disease, Cholelithiasis and Goiter. Essential Hypertension was present in 76.3% of cases. In more than 50% of the cases there was a combination of two or three nosological forms present. Depending on the replacement therapy used all patients were distributed into two groups: the main (300 patients) and the control one (165 patients).

Results of the study. Testosterone replacement therapy proved to contribute to normalization of mineral and lipid metabolism as well as improvement of kidney function and restoration of normal bone tissue density. Analysis of 5-year relapse frequency demonstrated it to be considerably lower in the main group (10%) than in the control one (30%) which is astatistically valid difference (p < 0.05).

Conclusion. Testosterone replacement therapy is a highly effective and safe method for urolithiasis therapy in males with hypogonadism.

About the authors

Nair S. Tagirov

Saint Petersburg Saint Elisabeth City Hospital

Author for correspondence.
Email: ruslana73nair@mail.ru

MD, PhD, Urologist

Russian Federation, Saint Petersburg

References

  1. Аляев Ю.Г., Руденко В.И. Современные аспекты медикаментозного лечения пациентов с мочекаменной болезнью // Эффективная фармакотерапия. - 2016. - № 41. - С. 10-15. [Alyaev YG, Rudenko VI. Modern aspects of drug treatment of patients with kidney stone disease. Effektivnaya farmakoterapiya. 2016;(41):10-15. (In Russ.)]
  2. Васильев А.Г., Комяков Б.К., Тагиров Н.С., Мусаев С.А. Чрескожная нефролитотрипсия в лечении коралловидного нефролитиаза // Вестник Санкт-Петербургской государственной медицинской академии им. И.И. Мечникова. - 2009. - № 4. - С. 183-186. [Vasiliev AG, Komyakov BK, Tagirov NS, Musaev SA. Percutaneous nephrolithitripsy in the treatment of coral calculus nephrolithiasis. Vestnik Sankt-Peterburgskoy gosudarstvennoy meditsinskoy akademii im. I.I. Mechnikova. 2009;(4):183-186. (In Russ.)]
  3. Васильев А.Г., Заславский Д.В., Трашков А.П., и др. Изменения гормонального статуса у пациентов с очаговым вульгарным псориазом // Вестник дерматологии и венерологии. - 2011. - № 5. - С. 88-90. [Vasilyev AG, Zaslavsky DV, Trashkov AP, et al. Changes in the hormonal status of patients with focal psoriasis vulgaris. Vestn Dermatol Venerol. 2011;(5):88-90. (In Russ.)]
  4. Тагиров Н.С., Назаров Т.Х., Васильев А.Г., и др. Опыт применения чрескожной нефролитотрипсии и контактной уретеролитотрипсии в комплексном лечении мочекаменной болезни // Профилактическая и клиническая медицина. - 2012. - № 4. - С. 30-33. [Tagirov NS, Nazarov TH, Vasilev AG, et al. The experience of using percutaneous nephrolithotripsy and contact ureterolithotripsy in the complex treatment of urolithiasis. Preventive and clinical medicine. 2012;(4):30-33. (In Russ.)]
  5. Трашков А.П., Панченко А.В., Каюкова Е.С., и др. Лейкемия Р-388 у мышей линии CDF1 как тест-система опухоль-ассоциированного неоангиогенеза и гиперкоагуляции // Бюллетень экспериментальной биологии и медицины. - 2014. - Т. 158. - № 10. - С. 500-502. [Trashkov AP, Panchenko AV, Kayukova ES, et al.Leykemiya R-388 u myshey linii CDF1 kak test-sistema opukhol’-assotsiirovannogo neoangiogeneza i giperkoagulyatsii. Biull Eksp Biol Med. 2014;158(10):500-502. (In Russ.)]
  6. Трашков А.П., Васильев А.Г., Коваленко А.Л., Тагиров Н.С. Метаболическая терапия мочекаменной болезни на различных моделях поражения почек у крыс // Экспериментальная и клиническая фармакология. - 2015. - Т. 78. - № 3. - С. 17-21. [Trashkov AP, Vasiliev AG, Kovalenko AL, Tagirov NS. Metabolic therapy of nephrolithiasis in two different rat models of kidney disease. Experimental and clinical pharmacology. 2015;78(3):17-21. (In Russ.)]
  7. Anaissie J, Roberts NH, Wang P, Yafi FA. Testosterone replacement therapy and components of the metabolic syndrome. Sex Med Rev. 2017;5(2):200-210. https://doi.org/10.1016/j.sxmr.2017.01.003.
  8. Akerman J, Kovac JR, Lipshultz LI. Testosterone therapy improves well being and psychological health. Curr Opin Urol. 2017;27(6):519-524. https://doi.org/10.1097/MOU.0000000000000440.
  9. Catakoglu AB, Kendirci M. Testosterone replacement therapy and cardiovascular events. Turk Kardiyol Dern Ars. 2017;45(7):664-672. https://doi.org/10.5543/tkda.2017.00531.
  10. Cunningham G, Belkoff L, Brock G, et al. Efficacy and safety of a new topical testosterone replacement gel therapy for the treatment of male hypogonadism. Endocr Pract. 2017;23(5):557-565. https://doi.org/10.4158/EP161665.OR.
  11. Diemer T, Hauptmann A, Wagenlehner FM. Testosterone therapy. Urologe A. 2016;55(4):539-548. https://doi.org/10.1007/s00120-016-0072-y.
  12. Fisang C, Anding R, Muller SC, et al. Urolithiasis - an interdisciplinary diagnostic, therapeutic and secondary preventive challenge. Dtsch Arztebl Int. 2015;112(6): 83-91. https://doi.org/10.3238/arztebl.2015.0083.
  13. Gee HY, Jun I, Braun DA, et al. Mutations in SLC26A1 Cause Nephrolithiasis. Am J Hum Genet. 2016;98(6):1228-1234. https://doi.org/10.1016/j.ajhg.2016.03.026.
  14. Goodale T, Sadhu A, Petak S, Robbins R. Testosterone and the Heart. Methodist Debakey Cardiovasc J. 2017;13(2):68-72. https://doi.org/10.14797/mdcj-13-2-68.
  15. Hwang K, Miner M. Controversies in testosterone replacement therapy: testosterone and cardiovascular disease. Asian J Androl. 2015;17(2):187-191. https://doi.org/10.4103/1008-682X.146968.
  16. Kaplan AL, Hu JC, Morgentaler A, et al. Testosterone therapy in men with prostate cancer. Eur Urol. 2016;69(5):894-903. https://doi.org/10.1016/j.eururo.2015.12.005.
  17. Levcikova M, Breza J, Jr., Luha J, et al. Testosterone replacement therapy (TRT) and its effect on bone marrow. How serious is it and is there a true polyglobulia? Bratisl Lek Listy. 2017;118(11):654-657. https://doi.org/10.4149/BLL_2017_124.
  18. Lee OD, Tillman K. An Overview of Testosterone therapy. Am J Mens Health. 2016;10(1):68-72. https://doi.org/10.1177/1557988314556671.
  19. Lo EM, Rodriguez KM, Pastuszak AW, Khera M. Alternatives to testosterone therapy: A Review. Sex Med Rev. 2018;6(1):106-113. https://doi.org/10.1016/j.sxmr.2017.09.004.
  20. Traish AM. Benefits and health implications of testosterone therapy in men with testosterone deficiency. Sex Med Rev. 2018;6(1):86-105. https://doi.org/10.1016/j.sxmr.2017.10.001.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Kidney function parameters on the background of testosterone replacement therapy

Download (20KB)
Indexing metadata
3. Fig. 2. Diurnal urine exertion

Download (37KB)
Indexing metadata
4. Fig. 3. Bone mineral density (g/cm3) on the background of androgen replacement therapy

Download (45KB)
Indexing metadata
5. Fig. 4. Base phophatase concentration

Download (38KB)
Indexing metadata
6. Fig. 5. Daily citrate excretion (norm — 422–840 mg/day)

Download (35KB)
Indexing metadata
7. Fig. 6. Daily magnesium excretion (norm — 3–5 mmol/day)

Download (33KB)
Indexing metadata
8. Fig. 7. Waist circumference in male patients on the background of androgen therapy

Download (28KB)
Indexing metadata
9. Fig. 8. Prostate volume (cm3)

Download (21KB)
Indexing metadata
10. Fig. 9. Urolithiasis relapse rate on the background of testosterone replacement therapy

Download (21KB)
Indexing metadata

Copyright (c) 2019 Tagirov N.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies